Income Tax Expense (Benefit) in USD of Tvardi Therapeutics, Inc. from 2012 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Tvardi Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and change rate from 2012 to Q1 2025.
  • Tvardi Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $0.000.
  • Tvardi Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending 31 Mar 2025 was -$398K.
  • Tvardi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was -$398K.
  • Tvardi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
  • Tvardi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Tvardi Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$398K $0 $0 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$398K -$398K -$398K 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025
Q3 2024 $0 $0 $0 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $0 $0 $0 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $0 $0 $0 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 $0 $0 $0 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025
Q3 2023 $0 $0 $0 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $0 $0 $0 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $0 $0 $0 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 $0 $0 $0 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2025
Q3 2022 $0 $0 $0 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $0 $0 $0 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 $0 $0 $0 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 $0 $0 +$255K 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024
Q3 2021 -$255K $0 +$132K 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$387K $0 +$182K 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 -$569K $0 +$122K 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 -$691K -$255K -$89K -53.6% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023
Q3 2020 -$602K -$132K +$198K +60% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$800K -$182K +$53K +22.6% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$853K -$122K -$37K -43.5% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$816K -$166K -$41K -32.8% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022
Q3 2019 -$775K -$330K -$264K -400% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$511K -$235K -$83K -54.6% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$428K -$85K -$39K -84.8% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 -$389K -$125K -$99K -381% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021
Q3 2018 -$290K -$66K +$79K +54.5% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 -$369K -$152K -$150K -7500% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019
Q1 2018 -$219K -$46K -$15K -48.4% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q4 2017 -$204K -$26K +$163K +86.2% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020
Q3 2017 -$367K -$145K -$90K -164% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018
Q2 2017 -$277K -$2K +$77K +97.5% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 -$354K -$31K +$114K +78.6% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018
Q4 2016 -$468K -$189K -$42K -28.6% 01 Oct 2016 31 Dec 2016 10-K 12 Mar 2019
Q3 2016 -$426K -$55K +$145K +72.5% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017
Q2 2016 -$571K -$79K -$44K -126% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017
Q1 2016 -$527K -$145K -$130K -867% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017
Q4 2015 -$397K -$147K -$5K -3.52% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2018
Q3 2015 -$392K -$200K -$168K -525% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016
Q2 2015 -$224K -$35K -$24K -218% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 -$200K -$15K +$1K +6.25% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016
Q4 2014 -$201K -$142K -$139K -4633% 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2017
Q3 2014 -$62K -$32K -$32K 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 -$30K -$11K +$9K +45% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015
Q1 2014 -$39K -$16K -$9K -129% 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015
Q4 2013 -$30K -$3K 01 Oct 2013 31 Dec 2013 10-K 11 Mar 2016
Q3 2013 $0 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014
Q2 2013 -$20K 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$7K 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014

Tvardi Therapeutics, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$398K -$398K 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025
2023 $0 $0 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025
2022 $0 $0 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2025
2021 $0 +$691K 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024
2020 -$691K +$125K +15.3% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023
2019 -$816K -$427K -110% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$389K -$185K -90.7% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 -$204K +$264K +56.4% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 -$468K -$71K -17.9% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$397K -$196K -97.5% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018
2014 -$201K -$171K -570% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017
2013 -$30K +$1K +3.23% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016
2012 -$31K 01 Jan 2012 31 Dec 2012 10-K 27 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.